Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Menopause and skin: new study reveals hidden links

NCT ID NCT07390305

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 100 women at different stages of menopause to see how skin aging in sun-exposed and non-exposed areas relates to hot flashes, mood, and sleep. Researchers measured skin wrinkles, color, elasticity, and moisture, and tracked sleep and symptoms at home for 30 days. The goal was to understand these connections, not to test any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Nov 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study enrolled adult women categorized into four distinct groups based on their reproductive aging stage according to the STRAW+10 staging system: a Young Control Group (aged 18-25, biological daughters of participants in the older groups, with regular menstrual cycles), an Early Perimenopausal Group (aged 45-50, with a persistent change in menstrual cycle length \>7 days), a Late Perimenopausal Group (aged 50-55, experiencing ≥2 consecutive cycles of ≥60 days or amenorrhea of ≥60 days), and a Postmenopausal Group (aged 55-60, with the last menstrual period occurring at least 12 months prior). All participants were recruited as mother-daughter pairs, where the young control group consisted of the biological daughters of participants in the late perimenopausal and postmenopausal groups .

Ages

18 to 60 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants must possess basic Chinese literacy skills (reading comprehension and expression) to complete questionnaires independently. 2. Voluntary participation and signed informed consent. 3. Willingness to comply with all study requirements and assessments. 4. Early Perimenopausal Group: 1. Healthy women aged 45-50 (±3) years. 2. STRAW Stage -2 / Early Perimenopause: Experiencing a persistent change in menstrual cycle length of \>7 days from their normal cycle, but with no occurrence of 60 or more days of amenorrhea (i.e., still having menstrual periods). 5. Late Perimenopausal Group: 1. Healthy women aged 50-55 (±3) years. 2. STRAW Stage -1 / Late Perimenopause: Experiencing ≥2 consecutive cycles with a length of ≥60 days, or the presence of ≥60 days of amenorrhea. 6\) Postmenopausal Group: <!-- --> 1. Healthy women aged 55-60 (±3) years. 2. STRAW Stage +1 / Postmenopause: Last menstrual period occurred at least 12 months prior. 7)Young Control Group: 1. Healthy women aged 18-25 (±3) years. 2. Biological daughters of participants in either the Late Perimenopausal Group or the Postmenopausal Group. 3. Regular menstrual cycle, with a cycle length ranging between 25-35 days. Exclusion Criteria 1. Presence of open wounds, clearly visible scars, acne marks, or other significant skin imperfections at the measurement sites. 2. History of skin diseases affecting the evaluation of the study areas (e.g., psoriasis, atopic dermatitis, skin cancer). 3. Women who are currently pregnant or breastfeeding. 4. Use of systemic estrogen or progesterone hormone replacement therapy within the past 6 months. 5. Presence of acute or severe chronic diseases currently under treatment. 6. Any known condition that significantly impairs cognitive or behavioral abilities. 7. Considered by the investigator or qualified professional to have other medical or specific reasons that may interfere with the evaluation of study results. 8. Early Perimenopausal Group \& Late Perimenopausal Group \& Postmenopausal Group: a) Current use of systemic hormone replacement therapy (HRT). b) Topical application of anti-aging products (e.g., retinoids, alpha/beta hydroxy acids) on the measurement areas within the past 3 months. c) History of breast cancer or oophorectomy. 9) Young Control Group: 1. Currently planning for pregnancy, pregnant, or lactating. 2. Diagnosis of Polycystic Ovary Syndrome (PCOS).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Genetic factors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai China-norm Quality Technical Service Co., Ltd.

    Shanghai, Shanghai Municipality, 200072, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.